Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Characteristics of mTORi-NB and S6K1i-NB.
  • Fig. S2. Myeloid cell–specific mTOR inhibition reduces atherosclerotic plaque inflammation.
  • Fig. S3. Systemic effects of mTORi-NB and S6K1i-NB treatment.
  • Fig. S4. Prosaposin colocalizes with macrophages in murine plaques.
  • Fig. S5. Psap mediates atherosclerotic plaque inflammation in Ldlr−/− mice.
  • Fig. S6. Nanobiologics inhibit oxLDL priming in human monocytes.
  • Fig. S7. PSAP mediates atherosclerotic plaque inflammation in humans.
  • Fig. S8. Correlation between PSAP expression and genes involved in mTOR signaling.
  • Fig. S9. Correlation between PSAP expression and genes involved in macrophage inflammation.
  • Table S1. Expression of genes coding for chemokines after mTORi-NB treatment.
  • Table S2. Expression of genes coding for chemokines after S6K1i-NB treatment.
  • Table S3. Expression of autophagy-related genes after mTORi-NB treatment.
  • Table S4. Expression of autophagy-related genes after S6K1i-NB treatment.
  • Table S5. Hub genes of the mTORi-NB–related turquoise module.
  • Table S6. Hub genes of the S6K1i-NB–related turquoise module.
  • Table S7. Correlation between PSAP expression and genes involved in mTOR signaling.
  • Table S8. Correlation between PSAP expression and genes involved in macrophage inflammation.
  • Legend for data file S1
  • References (6175)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). Individual subject-level data.